Atropine Sulfate Drug Study

Document Sample
Atropine Sulfate Drug Study Powered By Docstoc
					    NAME OF DRUG             CLASSIFICATION           MECHANISM OF ACTION                       INDICATION              CONTRAINDICATION                  ADVERSE EFFECTS                               NURSING RESPONSIBILITIES

GENERIC NAME:               Cardiovascular System   An anticholinergic that inhibits       • Symptomatic                • Contraindicated in           CNS:                              BEFORE:
atropine sulfate                    Drugs           acetylcholine at the                     bradycardia,                 patients hypersensitive to   Headache, restlessness,            1) Determine previous hypersensitivity to drug and its
                              (Ant-arrhythmics)     parasympathetic neuro-effector           bradyarrhythmia              drug                         ataxia, disorientation,               components.
TRADE NAME:                                         junction, blocking vagal effects, on     (junctional or escape      • Contraindicated in those     hallucinations, delirium,          2) Screen for impaired liver or kidney function which could
Sal-Tropine, Atro-Pen                               the SA & AV nodes, thereby               rhythm)                      with acute angle-closure     insomia, dizziness,                   alter the metabolism & excretion of the drug.
                                                    enhancing conduction through the       • Antidote for                 glaucoma, obstructive        excitement, agitation, fatigue,    3) Include screening for baseline status before beginning
MAXIMUM DOSE:                                       AV node and increasing the heart         anticholinesterase           uropathy, obstructive        confusion, drowsiness                 therapy & for any potential adverse effects.
2mg PO, IV 1mg every 5-60                           rate.                                    insecticide poisoning        disease of GI tract,         CV:                                4) Screen for brain damage, hypertension & spasticity.
min                                                                                        • Preoperatively to            paralytic ileus, toxic       Palpitations, bradycardia,         5) Screen for myasthenia gravis which could become much
                                                                                             diminish secretions and      megacolon, intestinal        tachycardia, hypertension or          worse with further blocking of the cholinergic receptors.
MINIMUM DOSE:                                                                                block cardio vagal           atony, unstable CV status    hypotension
0.2mg IV / IM every                                                                          reflexes                     in acute hemorrhage          GI:                               DURING:
30-60 min                                                                                  • Adjunct treatment of         tachycardia, myocardial       Dry mouth with thirst,            1) Ensure proper administration of the drug.
                                                                                             peptic ulcer disease,        ischemia, asthma or          dysphagia, loss of taste,          2) Ensure adequate hydration & temperature control.
AVAILABILITY:                                                                                functional GI                myasthenia gravis            nausea, vomiting,                  3) Watch for tachycardia in cardiac patients because it may lead
Injection:                                                                                   disturbances or            • Use cautiously in patients   constipation, delayed gastric         to ventricular fibrillation.
0.05mg/mL                                                                                    disorders such as            with Down Syndrome           emptying, antral stasis,           4) Monitor fluid intake & output. Drug causes urine retention &
0.1mg/mL                                                                                     irritable bowel              because they may be          paralytic ileus                       urinary hesitancy.
0.3 mg/mL                                                                                    syndrome                     more sensitive to drug       GU:                                5) Assess patient routinely for abdominal distention and
0.4 mg/mL                                                                                                                                              Urinary hesitancy& retention,         auscultate for bowel sound.
0.5 mg/mL                                                                                                                                              dysuria, impotence
0.8 mg/mL                                                                                                                                              EENT:                             AFTER:
                                                                                                                                                       Photophobia, blurred vision,       1) Instruct patient to take medication as directed,
CONTENT:                                                                                                                                               mydriasis, cycloplegia,            2) Teach patient receiving oral form of drug, how to handle
atropine sulfate                                                                                                                                       increased intraocular                 distressing anticholinergic effects.
                                                                                                                                                       pressure.                          3) Instruct patient to report serious or persistent adverse
PATIENT’S DOSE:                                                                                                                                        OTHER:                                reactions promptly.
No specific patient                                                                                                                                    anaphylaxis                        4) Instruct patient that oral rinsing & frequent oral hygiene can
                                                                                                                                                                                             relieve dry mouth.
                                                                                                                                                                                          5) Tell patient about potential for sensitivity of the eyes to the
                                                                                                                                                                                             sun & suggest use of sunglasses.

                                                                                           SOURCE:                     SOURCE:                         SOURCE:                           SOURCE:
SOURCE:                     SOURCE:                 SOURCE:                                 NDH 2005, p. 236            NDH 2005, p. 236                NDH 2005, p. 236                  NDH 2005, p. 237
 NDH 2005, p. 236            NDH 2005, p. 236        NDH 2005, p. 236                                                                                                                     NDG 2004 p. 96

                                                                                                                                                                                                                                 HERBERT ALMENDRAS HUYO

Shared By:
Description: Atropine Sulfate Drug Study